At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
NiCorddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
In Brief
A Phase 2 clinical trial evaluating NiCord for Sickle Cell Disease & Thalassemia. Completed, enrolled 16 participants across 3 sites.
Detailed Summary
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease & Thalassemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartSep 2012
Primary CompletionSep 2018
Study CompletionOct 2019
TodayJul 2026
First PostedMay 3, 2012
Enrollment StartSep 1, 2012
Primary CompletionSep 1, 2018
Study CompletionOct 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 14.2 years ago
Interventions
NiCorddrug
NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells